Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report)’s stock price fell 6.5% during mid-day trading on Wednesday . The company traded as low as $1.42 and last traded at $1.51. 63,476 shares changed hands during trading, an increase of 283% from the average session volume of 16,559 shares. The stock had previously closed at $1.61.
Alaunos Therapeutics Price Performance
The firm’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $2.05.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Recommended Stories
- Five stocks we like better than Alaunos Therapeutics
- What is the FTSE 100 index?
- Energy Transfer: Powering Data With Dividends and Diversification
- What Are Dividend Challengers?
- Qualcomm Stock Is Coiling for a Breakout
- What is the Shanghai Stock Exchange Composite Index?
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
